Circio Secures Funding to Boost RNA Technology Development
Targovax ASA (GB:0RIS) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Circio Holding ASA has successfully raised approximately NOK 10.7 million through warrant exercises and a private placement to advance its innovative circVec circular RNA technology. The capital injection, supported by strong investor demand and bolstered by new biotech investors, will accelerate development efforts and defer the need for further financing. This financial boost positions Circio to enhance its gene therapy program and explore novel cell therapy approaches.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
Trending Articles
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.